Langerhans cell histiocytosis (LCH) is a rare disease in which a specific type of immune cell grows out of control and accumulates in one or more organs, forming lesions that can damage tissue. It affects roughly 2.6 to 8.9 children per million under age 15 each year, with a median age at diagnosis of three years. Adults can also develop it, though far less frequently, at an estimated 1 to 1.5 cases per million annually.
LCH ranges from a single bone lesion that heals on its own to a life-threatening condition affecting the liver, spleen, and blood-forming system. Understanding where it falls on that spectrum is the key to knowing what to expect.
What Goes Wrong at the Cell Level
Langerhans cells are a type of immune cell normally found in the skin and mucous membranes. In LCH, precursor cells in the bone marrow acquire a genetic mutation that locks a growth-signaling pathway into the “on” position permanently. These abnormal cells then migrate into tissues, multiply, and recruit other immune cells, creating inflammatory lesions that erode bone, infiltrate organs, or disrupt hormone-producing glands.
The most common genetic driver is a specific mutation in a gene called BRAF, found in roughly 50 to 60% of pediatric cases and about 39% of adult cases. In the remaining patients, the same signaling pathway is typically activated by a different mutation, most often in a gene called MAP2K1, which accounts for around 30% of cases. The practical takeaway: nearly all LCH is driven by the same overactive growth signal, just triggered by slightly different genetic errors. This matters because targeted therapies can now block that signal directly.
Where LCH Shows Up in the Body
Bone is by far the most common site. About 80% of children with LCH develop one or more bone lesions, most often in the skull, eye socket, jaw, spine, ribs, or long bones of the arms and legs. These lesions can cause a visible lump or swelling, localized pain, headaches, back or neck pain, difficulty walking, or fractures.
Skin involvement occurs in roughly 40% of patients. The rash typically appears as reddish-brown or purplish bumps, scaly patches on the scalp, or eczema-like eruptions, often in the diaper area of infants or along the scalp and behind the ears. Because these skin changes closely mimic seborrheic dermatitis, psoriasis, eczema, or fungal infections, LCH skin disease is frequently misdiagnosed for weeks or months before a biopsy reveals the true cause. A rash that does not improve with standard treatments is often the clue that prompts further investigation.
The pituitary gland, a small hormone-producing structure at the base of the brain, is another common target. When LCH infiltrates the pituitary stalk, it most often causes central diabetes insipidus, a condition in which the body cannot properly regulate water balance. This leads to extreme thirst and excessive urination. Diabetes insipidus is the most frequent hormonal complication of LCH and can appear alongside or even years after other symptoms. On MRI, it shows up as thickening of the pituitary stalk and disappearance of a characteristic bright signal from the back of the gland.
Less commonly, LCH can affect the lungs (particularly in adult smokers), lymph nodes, liver, spleen, or gastrointestinal tract. Involvement of nearly every organ except the kidneys and gonads has been documented.
Single-System vs. Multisystem Disease
Doctors classify LCH based on how many organ systems are involved, because this is the strongest predictor of severity.
- Single-system LCH involves only one organ. It can be a single lesion (unifocal), such as one bone spot, or multiple lesions within the same organ (multifocal), such as bone lesions in several locations. This is the most common presentation and generally carries the best outlook.
- Multisystem LCH without risk-organ involvement affects two or more organs but does not involve the liver, spleen, or blood-forming system. While more serious than single-system disease, it is typically not life-threatening.
- Multisystem LCH with risk-organ involvement means the liver, spleen, or bone marrow is affected. This is the most dangerous form. High-risk patients are typically younger than two years old.
The distinction between “risk organs” and other sites is specifically about mortality risk. Chronic disease in lower-risk organs like bone or skin is rarely fatal, but repeated flares and tissue damage can still cause significant long-term problems, including permanent hearing loss, dental issues, bone deformities, or hormonal deficiencies.
How LCH Is Diagnosed
Diagnosis requires a tissue biopsy. A pathologist examines the sample under a microscope looking for the characteristic abnormal cells, then confirms the diagnosis using special staining techniques that detect specific proteins on the cell surface: CD1a and langerin (also called CD207). Both markers are highly specific to LCH cells. An older marker, S100, has traditionally been used alongside CD1a. When these markers are strongly positive in the right clinical context, the diagnosis is confirmed.
Once LCH is confirmed, imaging studies map the extent of disease. A full skeletal X-ray survey checks for bone lesions throughout the body. Blood work evaluates liver function and blood cell counts to determine whether risk organs are involved. MRI of the brain is performed if there are symptoms of diabetes insipidus or other neurological changes. Genetic testing of the biopsy tissue for the BRAF mutation helps guide treatment decisions.
Treatment by Disease Severity
Treatment depends entirely on how widespread the disease is.
For a single bone lesion, treatment may be as simple as surgical scraping (curettage) of the affected area, or sometimes a steroid injection directly into the lesion. Many isolated bone lesions heal without aggressive intervention, and some are discovered incidentally and monitored over time.
Multifocal bone disease and multisystem LCH typically require systemic chemotherapy. The standard first-line combination is vinblastine (a chemotherapy drug given by injection) paired with a corticosteroid, usually administered in an initial intensive phase followed by a longer maintenance phase that can last 12 months or more. Extending treatment duration has been shown to reduce the chance of relapse.
For patients whose disease does not respond to first-line therapy, or who carry the BRAF mutation and have severe multisystem disease, targeted drugs that specifically block the overactive BRAF protein have become an important option. These drugs can produce rapid and dramatic improvement, even in patients who have failed chemotherapy. However, the disease tends to return if the targeted drug is stopped, so the optimal duration of treatment is still being refined. Targeted therapy is also being explored for patients with other mutations in the same pathway.
Outlook and Long-Term Effects
Prognosis varies dramatically based on disease extent. Five-year event-free survival (meaning no relapse or progression) is about 95% for single-system disease. For multisystem disease without risk-organ involvement, that number drops to roughly 58%. With risk-organ involvement, it falls further to around 44%, though five-year overall survival in that group is still approximately 82%, meaning many patients who relapse can be salvaged with additional treatment.
Even after successful treatment, LCH can leave lasting effects. Diabetes insipidus, once established, is usually permanent and requires lifelong hormone replacement. Other pituitary hormone deficiencies can develop over time, affecting growth, thyroid function, or puberty. Bone lesions near the ear can cause permanent hearing loss. Vertebral lesions may lead to spinal compression or chronic pain.
A particularly challenging late complication is a neurodegenerative syndrome that can develop years after the original diagnosis. This involves progressive problems with coordination, tremor, difficulty with speech, cognitive changes, and behavioral issues. It appears on MRI as characteristic changes in the cerebellum and other brain regions. The neurodegenerative form of LCH is distinct from active tumor-like brain lesions and is thought to represent an ongoing inflammatory process rather than direct tumor infiltration. It remains one of the most difficult aspects of LCH to treat, and long-term neurological monitoring is important for patients who had disease near the skull base or pituitary gland.
Because of these potential late effects, children and adults treated for LCH benefit from ongoing follow-up that extends well beyond the end of active treatment, with periodic monitoring of hormone levels, hearing, neurological function, and imaging of previously affected sites.